Breast Cancer: DATROWAY® Approved in U.S. for Metastatic HR Positive, HER2 Negative Type
Breast Cancer: DATROWAY® Approved in U.S. for Metastatic HR Positive, HER2 Negative Type DATROWAY® (datopotamab deruxtecan-dlnk), an innovative TROP2-directed antibody-drug conjugate (ADC), has been approved by the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable or…
Arrowhead Announces FDA NDA Acceptance of Plozasiran
Arrowhead Announces FDA NDA Acceptance of Plozasiran Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational plozasiran as a treatment for familial chylomicronemia syndrome (FCS),…
ImmunoPrecise Antibodies Realigns Pipeline with AI and First-Principles Innovation
ImmunoPrecise Antibodies Realigns Pipeline with AI and First-Principles Innovation ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today unveiled its AI-powered pipeline, designed to revolutionize therapeutic development. This new system combines cutting-edge artificial intelligence with first-principles thinking, creating the BioStrand pipeline. By reimagining…
Announces Milestone KarXT NDA Acceptance for Schizophrenia, Zai Lab
Announces Milestone KarXT NDA Acceptance for Schizophrenia, Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announces that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT as a treatment for schizophrenia in…
Announces TripleBlind Exchange: Selfii’s Secure HIPAA-Compliant Health Data Access
Announces TripleBlind Exchange: Selfii’s Secure HIPAA-Compliant Health Data Access Selfii, a leader in privacy-preserving health data solutions for individuals and healthcare organizations, announces the launch of its groundbreaking data marketplace, TripleBlind Exchange. This innovative platform provides secure, HIPAA/GDPR-compliant access to…
Healthcare Innovation: WorldQuant Foundry Names Dr. Christopher Mason Senior Advisor
Healthcare Innovation: WorldQuant Foundry Names Dr. Christopher Mason Senior Advisor WorldQuant Foundry, a platform focused on empowering entrepreneurial ventures with data-driven insights and AI-powered solutions, is excited to announce the appointment of Dr. Christopher Mason as Senior Healthcare Advisor. Dr.…
FDA Approves FoundationOne®CDx for OJEMDA™ in Pediatric Brain Tumor
FDA Approves FoundationOne®CDx for OJEMDA™ in Pediatric Brain Tumor Foundation Medicine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FoundationOne®CDx as a companion diagnostic for Day One Biopharmaceuticals’ OJEMDA, a type II RAF inhibitor. This…
MedTech Industry Expansion: NAMSA Acquires WuXi AppTec’s U.S. Testing Operations
MedTech Industry Expansion: NAMSA Acquires WuXi AppTec’s U.S. Testing Operations NAMSA, a leading global provider of testing, clinical, and regulatory services for the MedTech industry, has announced an agreement to acquire the medical device testing facilities of WuXi AppTec located…
Award Akamai Finalist: Castle’s DecisionDx®-SCC Poster at Maui Derm Hawaii 2025
Award Akamai Finalist: Castle’s DecisionDx®-SCC Poster at Maui Derm Hawaii 2025 Castle Biosciences, Inc. (Nasdaq: CSTL), a company committed to improving patient care through innovative diagnostic tests, will present new data from its dermatologic test portfolio at the Maui Derm…
Agreement Between Neuraly and Enigma Biomedical USA on PET Imaging Biomarker PMI04
Agreement Between Neuraly and Enigma Biomedical USA on PET Imaging Biomarker PMI04 On January 16, 2025, Neuraly Inc., a wholly owned subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA, Inc. revealed that they have signed a research license and…
Appoints Joseph Oliverio as President and CEO of Actineer
Appoints Joseph Oliverio as President and CEO of Actineer Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., appoints Joseph Oliverio as its President and Chief Executive Officer. With more than 30 years of leadership experience in…
Atara Biotherapeutics Provides Update on EBVALLO™ (tabelecleucel)
Atara Biotherapeutics Provides Update on EBVALLO™ (tabelecleucel) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for EBVALLO™…